SCT-I10A + SCT200 + capecitabine + oxaliplatin

**SCT-I10A + SCT200 + capecitabine + oxaliplatin** is a four-drug combination regimen. Capecitabine is an oral prodrug of fluorouracil, functioning as an antimetabolite that inhibits DNA synthesis in rapidly dividing cells[2][3][5][6]. Oxaliplatin is a platinum-based alkylating agent that induces DNA crosslinking, resulting in apoptosis of cancer cells[5][6]. The modalities of SCT-I10A and SCT200 are not well-defined in publicly available sources, but based on code naming conventions, they are likely investigational biologics, possibly monoclonal antibodies, used in oncology combination therapy. This combination is primarily being explored for advanced or metastatic colorectal cancer, but may potentially be applicable to other solid tumors[2][5][6][7][8]. Capecitabine and oxaliplatin (frequently referred to as CAPOX or XELOX) are approved and widely used for colorectal, gastric, and biliary cancers[3][5][6][7]. The mechanism, safety, and efficacy of capecitabine + oxaliplatin have been established in phase III trials[2][6]. SCT-I10A and SCT200 are investigational and no detailed mechanism or regulatory status is available. The overall combination likely leverages cytotoxic chemotherapy plus biologic targeting.

Other names

CAPOXXELOX